{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:32:04Z","timestamp":1791304324874,"version":"4.3.1"},"reference-count":23,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T00:00:00Z","timestamp":1739059200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T00:00:00Z","timestamp":1739059200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2025,6]]},"abstract":"ABSTRACT<\/jats:title>\n \n Background<\/jats:title>\n The introduction of immune checkpoint inhibitors (ICIs) opened a new era in cancer immunotherapy. In particular, PD\u20101 inhibitors have shown remarkable efficacy in various cancers, most notably melanoma. However, the widespread use of immune checkpoint inhibitors comes with the challenge of immune\u2010related adverse events (irAEs), with cutaneous toxicities being the most prevalent.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n A retrospective, single\u2010center study was carried out to investigate the cutaneous side effects in patients diagnosed with melanoma and treated with PD\u20101 inhibitors (pembrolizumab or nivolumab) at the Department of Dermatology, Venereology, and Oncodermatology, University of P\u00e9cs, Hungary. The study included patients with stage III or IV melanoma who received PD\u20101 inhibitor monotherapy, either for metastatic or adjuvant purposes, from August 2015 to May 2022.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A cohort of 174 patients was examined, with 29% experiencing cutaneous adverse events (cAEs). The most prevalent cutaneous toxicities were vitiligo (\n n<\/jats:italic>\n \u2009=\u200918; 27%), maculopapular rash (\n n<\/jats:italic>\n \u2009=\u200914; 21%), pruritus (\n n<\/jats:italic>\n \u2009=\u200914; 21%), xerostomia (\n n<\/jats:italic>\n \u2009=\u20098; 12%), and lichenoid dermatitis (\n n<\/jats:italic>\n \u2009=\u20094; 6%). Treatment primarily involved topical corticosteroids and emollients, with a few cases requiring systemic therapy. Notably, the occurrence of dermatologic adverse events was associated with improved progression\u2010free survival (PFS) (\n p<\/jats:italic>\n \u2009=\u20090.007) and overall survival (OS) (\n p<\/jats:italic>\n \u2009=\u20090.026) compared to those without any skin toxicity (\n p<\/jats:italic>\n \u2009<\u20090.0001), emphasizing their potential prognostic significance. Our data were not influenced by any well\u2010known prognostic factors of melanoma.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Our study contributes to the growing body of evidence supporting the prognostic value of cutaneous adverse events in patients treated with PD\u20101 inhibitors. Optimizing treatment strategies while maintaining oncologic therapy is essential, highlighting the role of dermatologists in multidisciplinary cancer care.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/ijd.17683","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T02:55:09Z","timestamp":1739242509000},"page":"1066-1078","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cutaneous Side Effects of\n PD<\/scp>\n \u20101 Inhibitors: A Single\u2010Center Retrospective Study"],"prefix":"10.1111","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4990-1366","authenticated-orcid":false,"given":"Mel\u00e1nia","family":"Pozsgai","sequence":"first","affiliation":[{"name":"Department of Dermatology Venerology and Oncodermatology Clinical Center, University of P\u00e9cs P\u00e9cs Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udoh Frieda\u2010Rex","family":"Sebastian","sequence":"additional","affiliation":[{"name":"Malta Foundation Program Mater Dei Hospital Msida Malta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Ol\u00e1h","sequence":"additional","affiliation":[{"name":"Department of Dermatology Venerology and Oncodermatology Clinical Center, University of P\u00e9cs P\u00e9cs Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikt\u00f3ria","family":"N\u00e9meth","sequence":"additional","affiliation":[{"name":"Department of Dermatology Venerology and Oncodermatology Clinical Center, University of P\u00e9cs P\u00e9cs Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolland","family":"Gyulai","sequence":"additional","affiliation":[{"name":"Department of Dermatology Venerology and Oncodermatology Clinical Center, University of P\u00e9cs P\u00e9cs Hungary"},{"name":"Department of Dermatology and Allergology Albert Szent\u2010Gy\u00f6rgyi Clinical Center, University of Szeged Szeged Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Lengyel","sequence":"additional","affiliation":[{"name":"Department of Dermatology Venerology and Oncodermatology Clinical Center, University of P\u00e9cs P\u00e9cs Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,2,9]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1136"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16311"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0336-3"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-020-05701-9"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29040234"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2016.12.001"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.02.010"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.05.035"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17855"},{"issue":"2","key":"e_1_2_6_11_1","first-page":"73","article-title":"Skin Manifestations Associated With Checkpoint Inhibitors","volume":"1","author":"Nazzaro G.","year":"2022","journal-title":"Journal of the European Academy of Dermatology and Venereology: Clinical Practice"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.10.029"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2021.09.002"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1101a155"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-0384-3"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.1916"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.035"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15345"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2019.34.e186"},{"issue":"1","key":"e_1_2_6_20_1","first-page":"123","article-title":"Cutaneous Toxicities of Immune Checkpoint Inhibitors: The Role of the Dermatologist","volume":"93","author":"Tattersall I. W.","year":"2020","journal-title":"Yale Journal of Biology and Medicine"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-021-09976-0"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.2707"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16152656"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.1389"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.17683","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijd.17683","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.17683","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T17:34:50Z","timestamp":1770917690000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.17683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,9]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1111\/ijd.17683"],"URL":"https:\/\/doi.org\/10.1111\/ijd.17683","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,9]]},"assertion":[{"value":"2024-08-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}